Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Sanofi launches Afrezza inhalable insulin for diabetes treatment

Single-dose cartridges and a small, discreet, and easy-to-use inhaler give patients an option to injections to help with glycemic control in adults with diabetes.

Single-dose cartridges and a small, discreet, and easy-to-use inhaler give patients an option to injections to help with glycemic control in adults with diabetes.
Single-dose cartridges and a small, discreet, and easy-to-use inhaler give patients an option to injections to help with glycemic control in adults with diabetes.

Global healthcare leader Sanofi and biopharmaceutical company MannKind Corp. announced that Afrezza® (insulin human) Inhalation Powder is now available by prescription in U.S. retail pharmacies nationwide.

Afrezza® is a registered trademark of MannKind Corp., is manufactured by MannKind Corp., and distributed by Sanofi-aventis U.S. LLC. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes.

In a press release announcing that FDA had approved Afrezza to treat diabetes, the agency said, “The drug’s safety and effectiveness were evaluated in a total of 3,017 participants–1,026 participants with type 1 diabetes and 1,991 patients with type 2 diabetes.”

FDA added, “Afrezza has a Boxed Warning advising that acute bronchospasm has been observed in patients with asthma and chronic obstructive pulmonary disease (COPD). Afrezza should not be used in patients with chronic lung disease, such as asthma or COPD because of this risk. The most common adverse reactions associated with Afrezza in clinical trials were hypoglycemia, cough, and throat pain or irritation.”

Sanofi and MannKind entered into a worldwide exclusive licensing agreement to develop and commercialize Afrezza. Under the collaboration agreement, Sanofi is responsible for global commercial, regulatory, and development activities.

“Many people living with diabetes are not able to control their blood sugar on their current medications and may benefit from using insulin. Now they have another option to administer insulin that is not an injection," says Dr. Janet McGill, M.D., Professor of Medicine at Washington University School of Medicine in St. Louis and Afrezza clinical trial investigator. "This delivery option may help change the dialogue between health care professionals and people living with diabetes about initiating or intensifying insulin therapy."

Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO